A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
- Author
- SCHMID, P1 ; KÜHNHARDT, D2 ; FREIER, W10 ; KÜMMEL, S11 ; VAN DE VELDE, H12 ; REGIERER, A2 ; POSSINGER, K2 ; KIEWE, P3 ; LEHENBAUER-DEHM, S2 ; SCHIPPINGER, W4 ; GREIL, R5 ; LANGE, W6 ; PREISS, J7 ; NIEDERLE, N8 ; BROSSART, P9
[1] Medical Oncology, Imperial College London, Charing Cross Hospital, London, United Kingdom
[2] Department of Oncology and Haematology, Charite Campus Mitte, Berlin, Germany
[3] Department of Haematology, Oncology and Transfusion Medicine, Charite Campus Benjamin Franklin, Berlin, Germany
[4] Department of Oncology and Haematology, Universitaetsklinikum, Graz, Austria
[5] 3rd Medical Department of Oncology and Haematology, Private Medical University Hospital Salzburg, Salzburg, Austria
[6] Department of Oncology and Haematology, Johanniter-Krankenhaus Rheinhausen, Duisburg, Germany
[7] Department of Oncology and Haematology, Caritasklinik St Theresia, Saarbrücken, Germany
[8] Department of Oncology and Haematology, Klinikum Leverkusen, Leverkusen, Germany
[9] Department of Oncology and Haematology, Universitatsklinikum, Tübingen, Germany
[10] Practice for Oncology and Haematology, Hildesheim, Germany
[11] Department of Gynecology and Obstetrics, University of Duisburg-Essen, Duisburg, Germany
[12] Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium - Source
Annals of oncology. 2008, Vol 19, Num 5, pp 871-876, 6 p ; ref : 20 ref
- ISSN
- 0923-7534
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- bortezomib capecitabine chemotherapy metastatic breast cancer phase I study proteasome inhibition
- Keyword (fr)
- Anthracyclines Anticancéreux Bortézomib Cancer du sein Capécitabine Chimiothérapie Dérivé du taxane Essai clinique phase I Essai clinique phase II Homme Inhibiteur du protéasome Métastase Stade avancé Traitement Acide boronique Analogue Cancer Dipeptide Dérivé de la fluoropyrimidine Pathologie de la glande mammaire Pathologie du sein Pyrimidine nucléoside Tumeur maligne
- Keyword (en)
- Anthracyclins Antineoplastic agent Bortezomib Breast cancer Capecitabine Chemotherapy Taxane derivatives Phase I trial Phase II trial Human Proteasome inhibitor Metastasis Advanced stage Treatment Analog Cancer Dipeptides Fluoropyrimidine derivatives Mammary gland diseases Breast disease Pyrimidine nucleoside Malignant tumor
- Keyword (es)
- Antraciclinas Anticanceroso Bortezomib Cáncer del pecho Capecitabina Quimioterapia Taxane derivado Ensayo clínico fase I Ensayo clínico fase II Hombre Inhibidor proteasome Metástasis Estadio avanzado Tratamiento Análogo Cáncer Dipéptido Fluoropirimidina derivado Glándula mamaria patología Seno patología Pirimidina nucleósido Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20379197
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/annonc/mdm569 
https://dx.doi.org/10.1093/annonc/mdm569
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm569\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:145:\"A phase I\/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and\/or anthracyclines\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"871\";s:8:\"\u0000*\u0000epage\";s:3:\"876\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SCHMID\";s:10:\"\u0000*\u0000aufirst\";s:1:\"P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:13:\"K\u00dcHNHARDT, D\";i:1;s:9:\"FREIER, W\";i:2;s:10:\"K\u00dcMMEL, S\";i:3;s:15:\"VAN DE VELDE, H\";i:4;s:11:\"REGIERER, A\";i:5;s:12:\"POSSINGER, K\";i:6;s:8:\"KIEWE, P\";i:7;s:18:\"LEHENBAUER-DEHM, S\";i:8;s:14:\"SCHIPPINGER, W\";i:9;s:8:\"GREIL, R\";i:10;s:8:\"LANGE, W\";i:11;s:9:\"PREISS, J\";i:12;s:11:\"NIEDERLE, N\";i:13;s:11:\"BROSSART, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:145:\"A phase I\/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and\/or anthracyclines\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm569\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:145:\"A phase I\/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and\/or anthracyclines\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"871\";s:8:\"\u0000*\u0000epage\";s:3:\"876\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SCHMID\";s:10:\"\u0000*\u0000aufirst\";s:1:\"P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:13:\"K\u00dcHNHARDT, D\";i:1;s:9:\"FREIER, W\";i:2;s:10:\"K\u00dcMMEL, S\";i:3;s:15:\"VAN DE VELDE, H\";i:4;s:11:\"REGIERER, A\";i:5;s:12:\"POSSINGER, K\";i:6;s:8:\"KIEWE, P\";i:7;s:18:\"LEHENBAUER-DEHM, S\";i:8;s:14:\"SCHIPPINGER, W\";i:9;s:8:\"GREIL, R\";i:10;s:8:\"LANGE, W\";i:11;s:9:\"PREISS, J\";i:12;s:11:\"NIEDERLE, N\";i:13;s:11:\"BROSSART, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:145:\"A phase I\/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and\/or anthracyclines\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm569\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm569\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:145:\"A phase I\/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and\/or anthracyclines\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"871\";s:8:\"\u0000*\u0000epage\";s:3:\"876\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SCHMID\";s:10:\"\u0000*\u0000aufirst\";s:1:\"P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:13:\"K\u00dcHNHARDT, D\";i:1;s:9:\"FREIER, W\";i:2;s:10:\"K\u00dcMMEL, S\";i:3;s:15:\"VAN DE VELDE, H\";i:4;s:11:\"REGIERER, A\";i:5;s:12:\"POSSINGER, K\";i:6;s:8:\"KIEWE, P\";i:7;s:18:\"LEHENBAUER-DEHM, S\";i:8;s:14:\"SCHIPPINGER, W\";i:9;s:8:\"GREIL, R\";i:10;s:8:\"LANGE, W\";i:11;s:9:\"PREISS, J\";i:12;s:11:\"NIEDERLE, N\";i:13;s:11:\"BROSSART, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:145:\"A phase I\/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and\/or anthracyclines\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm569\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:145:\"A phase I\/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and\/or anthracyclines\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"871\";s:8:\"\u0000*\u0000epage\";s:3:\"876\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SCHMID\";s:10:\"\u0000*\u0000aufirst\";s:1:\"P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:13:\"K\u00dcHNHARDT, D\";i:1;s:9:\"FREIER, W\";i:2;s:10:\"K\u00dcMMEL, S\";i:3;s:15:\"VAN DE VELDE, H\";i:4;s:11:\"REGIERER, A\";i:5;s:12:\"POSSINGER, K\";i:6;s:8:\"KIEWE, P\";i:7;s:18:\"LEHENBAUER-DEHM, S\";i:8;s:14:\"SCHIPPINGER, W\";i:9;s:8:\"GREIL, R\";i:10;s:8:\"LANGE, W\";i:11;s:9:\"PREISS, J\";i:12;s:11:\"NIEDERLE, N\";i:13;s:11:\"BROSSART, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:145:\"A phase I\/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and\/or anthracyclines\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm569\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:145:\"A phase I\/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and\/or anthracyclines\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"871\";s:8:\"\u0000*\u0000epage\";s:3:\"876\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SCHMID\";s:10:\"\u0000*\u0000aufirst\";s:1:\"P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:13:\"K\u00dcHNHARDT, D\";i:1;s:9:\"FREIER, W\";i:2;s:10:\"K\u00dcMMEL, S\";i:3;s:15:\"VAN DE VELDE, H\";i:4;s:11:\"REGIERER, A\";i:5;s:12:\"POSSINGER, K\";i:6;s:8:\"KIEWE, P\";i:7;s:18:\"LEHENBAUER-DEHM, S\";i:8;s:14:\"SCHIPPINGER, W\";i:9;s:8:\"GREIL, R\";i:10;s:8:\"LANGE, W\";i:11;s:9:\"PREISS, J\";i:12;s:11:\"NIEDERLE, N\";i:13;s:11:\"BROSSART, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:145:\"A phase I\/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and\/or anthracyclines\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
